Skip to main content
Figure 3 | BMC Nephrology

Figure 3

From: Higher anti-depressant dose and major adverse outcomes in moderate chronic kidney disease: a retrospective population-based study

Figure 3

Association between anti-depressant dose and adverse events in patients with and without Chronic Kidney Disease (CKD) where the presence of CKD was defined by an estimated glomerular filtration rate (eGFR) < 45 mL/min per 1.73 m 2 . All point estimates of the relative risk with a higher vs. lower anti-depressant dose and outcomes were below a value of 1 in patients with and without CKD, with the association not appreciably different in those with and without CKD. Adjusted for 15 covariates: antidepressant type, age, sex, year of cohort entry, modified Charlson score (a co-morbidity index), and concurrent medication use (anticonvulsants, gabapentin, antipsychotics, barbiturates, benzodiazepines, histamine2-receptor antagonists, dopamine agonists, muscle relaxants, opioids and overactive bladder medications). Abbreviations: CI, confidence interval; CT, computed tomography.

Back to article page